Expression of CD markers in JAK2V617F positive myeloproliferative neoplasms: Prognostic significance

Shahrabi, Saeid; Ehsanpour, Ali; Heidary, Somayyeh; Shahjahani, Mohammad; Behzad, Masumeh Maleki

doi:10.4081/oncol.2018.373

Cited by 3 publications

(2 citation statements)

References 132 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, and as previously mentioned, the expression of CD177 ( PRV-1 ), a GPI-linked cell surface glycoprotein with a role in neutrophil activation, was increased in PV patients, and to a lesser extent in ET and PMF patients [ 64 , 65 ]. Indeed, higher CD177 expression was associated with an increased risk of thrombotic and bleeding complications due to increased circulating neutrophils [ 173 , 174 ]. For a complete and recent review on the role of neutrophils in thrombosis, we refer readers to the article by Ferrer-Marín and colleagues published in this special edition [ 175 ].…”

Section: Prognosismentioning

confidence: 99%

Recent Advances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera

Stuckey

Gómez‐Casares

2021

IJMS

View full text Add to dashboard Cite

Genetic studies in the past decade have improved our understanding of the molecular basis of the BCR-ABL1-negative myeloproliferative neoplasm (MPN) polycythaemia vera (PV). Such breakthroughs include the discovery of the JAK2V617F driver mutation in approximately 95% of patients with PV, as well as some very rare cases of familial hereditary MPN caused by inherited germline mutations. Patients with PV often progress to fibrosis or acute myeloid leukaemia, both associated with very poor clinical outcome. Moreover, thrombosis and major bleeding are the principal causes of morbidity and mortality. As a result of increasingly available and economical next-generation sequencing technologies, mutational studies have revealed the prognostic relevance of a few somatic mutations in terms of thrombotic risk and risk of transformation, helping to improve the risk stratification of patients with PV. Finally, knowledge of the molecular basis of PV has helped identify targets for directed therapy. The constitutive activation of the tyrosine kinase JAK2 is targeted by ruxolitinib, a JAK1/JAK2 tyrosine kinase inhibitor for PV patients who are resistant or intolerant to cytoreductive treatment with hydroxyurea. Other molecular mechanisms have also been revealed, and numerous agents are in various stages of development. Here, we will provide an update of the recent published literature on how molecular testing can improve the diagnosis and prognosis of patients with PV and present recent advances that may have prognostic value in the near future.

show abstract

Section: Prognosismentioning

confidence: 99%

Recent Advances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera

Stuckey

Gómez‐Casares

2021

IJMS

View full text Add to dashboard Cite

show abstract

“…The phenotype of the involved cells, often characterized by the expression of surface CD markers, is another feature playing an essential role in the diagnosis and prognosis of hematological malignancies and solid tumors. 3 , 71 , 72 Although flow cytometry is a practical technique to analyze the expression levels of CD markers, genetic alterations (including SNPs) affecting expression patterns of CD markers may cause significant limitations in the classification and precise prognosis of hematological malignancies. 73-75 As an example, CD38 rs6449182 is a known polymorphism in CLL and it has been shown that patients carrying the GG genotype of this polymorphism have more aggressive disease.…”

Section: Discussion and Future Perspectivementioning

confidence: 99%

CD markers polymorphisms as prognostic biomarkers in hematological malignancies

et al. 2020

Self Cite

View full text Add to dashboard Cite

The clusters of differentiation (CD) are surface molecules used for immunophenotyping of cells. The expression of CD markers is widely used to classify hematological malignancies, including leukemia and lymphoma. Single nucleotide polymorphisms (SNPs) are crucial genetic changes that can be associated with abnormal expression and function of CD markers. In this paper, we assess the prognostic effect of CD markers’ SNPs in hematological malignancies. Materials and methods and relevant literature was identified by a PubMed search (2001-2019) of English language papers using the following terms: ‘polymorphism’, ‘CD marker’, ‘leukemia’, ‘lymphoma’, ‘prognosis’, ‘CD marker’, and ‘polymorphism’. Many studies have demonstrated the effects of CD markers’ polymorphisms on risk of hematological malignancies. Also, SNPs of CD markers can be related with clinicopathological features, invasiveness, and response to therapy of these disorders. Considering the importance of SNPs in the expressions of CD markers, these genetic changes could be used as potential prognostic biomarkers in hematological malignancies. It is hoped that the evaluation of SNPs in CD markers will enable early diagnosis, prognosis, and detection of response to treatment. However, better understanding of SNPs in CD markers that are involved in hematological malignancies requires further studies on different populations of the worldwide.

show abstract

Apoptosis and genes involved in oral cancer - a comprehensive review

et al. 2020

View full text Add to dashboard Cite

Oral cancers needs relentless research due to high mortality and morbidity associated with it. Despite of the comparable ease in accessibility to these sites, more than 2/3rd cases are diagnosed in advanced stages. Molecular/genetic studies augment clinical assessment, classification and prediction of malignant potential of oral lesions, thereby reducing its incidence and increasing the scope for early diagnosis and treatment of oral cancers. Herein we aim to review the role of apoptosis and genes associated with it in oral cancer development in order to aid in early diagnosis, prediction of malignant potential and evaluation of possible treatment targets in oral cancer. An internet-based search was done with key words apoptosis, genes, mutations, targets and analysis to extract 72 articles after considering inclusion and exclusion criteria. The knowledge of genetics and genomics of oral cancer is of utmost need in order to stop the rising prevalence of oral cancer. Translational approach and interventions at the early stage of oral cancer, targeted destruction of cancerous cells by silencing or promoting involved genes should be the ideal intervention.

show abstract

Expression of CD markers in JAK2V617F positive myeloproliferative neoplasms: Prognostic significance

Cited by 3 publications

References 132 publications

Recent Advances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera

Recent Advances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera

CD markers polymorphisms as prognostic biomarkers in hematological malignancies

Apoptosis and genes involved in oral cancer - a comprehensive review

Contact Info

Product

Resources

About